SEATTLE, May 31 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. , a biopharmaceutical company developing treatments for autoimmune disease and cancer, today announced that data regarding the company's TRU-016 program will be presented at the 43rd ASCO Annual Meeting being held June 1-5, 2007 at McCormick Place, Chicago, Illinois. Trubion's poster session details are as follows:
Poster Title: Depletion of Normal and Malignant B Cells with a CD37- specific SMIP Molecule Poster Number: G1 Abstract No: 3063 Presenter: Charles Cerveny, MS Time: Sunday, June 3, 2007 8:00 AM - 12:00 PM
A copy of the poster will be made available in the Investors' section of Trubion's web site after the poster has been presented (http://investors.trubion.com/events.cfm).
About Trubion
Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months the Company designed, developed and submitted to the FDA an Investigational New Drug application for, its lead product candidate, TRU-015, which is currently being tested in a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit www.trubion.com .
Forward-Looking Statements
Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's ability to successfully conduct clinical trials for TRU-015 and other SMIP(TM) product candidates, the uncertainty of the FDA approval process and other regulatory requirements, the therapeutic and commercial value of Trubion's drug candidates, the company's Wyeth collaboration, including its ability to receive milestone payments from Wyeth, and risks associated with defending and enforcing any patent claims or other intellectual property rights; and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended March 31, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
TRBN-G Contact: Jim DeNike Senior Director, Corporate Communications Trubion Pharmaceuticals, Inc. 206-838-0500
Trubion Pharmaceuticals, Inc.CONTACT: Jim DeNike, Senior Director of Trubion Pharmaceuticals, Inc.,Corporate Communications, +1-206-838-0500
Web site: http://www.trubion.com//
